ArticleFrontiers in molecular medicine2026
Blood biomarkers and atrial remodeling in patients at risk of atrial fibrillation.
Article in Frontiers in molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Arterial hypertension and endurance training are related to left atrial (LA) remodeling and risk of atrial fibrillation (AF). Serum blood biomarkers have been explored in relation to cardiovascular risk. Our aim was to assess the influence of patient and echocardiographic characteristics on serum blood biomarkers in individuals at risk for AF. Methods: A population of 511 subjects was analyzed: 286 endurance athletes and 225 patients with arterial hypertension. Participants underwent 2D and 3D echocardiography with speckle-tracking analysis. Blood samples were obtained to evaluate biomarkers of myocardial damage (Brain Natriuretic Peptide, troponin I, Oncostatin M, heart-type Fatty Acid-Binding Protein and Placenta Growth Factor), vascular endothelial dysfunction (Endothelial cell-specific molecule 1), and fibrosis (Matrix Metalloproteinase 1, 2 and 9, C-X-C motif chemokine ligand 6 and 16, and Galectin-3 (Gal-3)). Linear regression models were fitted to discern the relationship of patient and echo characteristics and serum biomarker levels. Results: The results revealed the significant influence of age, gender, body mass index and renal function on biomarker levels. Parameters of myocardial damage showed a limited range of values in our cohort with no differences between groups. Biomarkers of fibrosis were uniformly elevated in hypertension, with Gal-3 levels independently associated with LA reservoir strain. Conclusion: Serum levels of fibrosis biomarkers differ between populations at risk for AF. In hypertension Gal-3 levels are associated with LA reservoir function, making it a potential biomarker for LA remodeling in this setting. Clinical follow-up is needed to relate these findings with clinical outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.